Purpose
The prognosis for metastatic colorectal cancer is grave. Whether to perform surgical resection or palliative treatment remains controversial for this advanced disease. In this retrospective study, we collected data from patients with Stage IV colorectal cancer to identify prognostic factors for predicting selection criteria for surgical treatment in patients with metastatic disease. METHODS: A retrospective chart review was performed for patients treated from 1992 to 1999 from the Koo Foundation Sun Yat-Sen Cancer Center Tumor Registry. Seventy-four patients were identified as having Stage IV disease at the time of diagnosis. Data concerning the patients’ demographics, laboratory results, operative procedure, mortality, morbidity, and survival were collected. Independent variables and survival time were analyzed by the independent Mest method. The difference was considered statistically significant at P < 0.05. RESULTS: Overall survival time for the patients with Stage IV colorectal cancer was 16.1 months. Survival in the curative resection group was significantly longer than that in the noncurative group (31.9 vs. 12.7; P < 0.016). The operative mortality and morbidity rates were 5.6 percent (4 of 71) and 21.1 percent (15 of 71), respectively. The two most common complications were leakage at the site of anastomosis and urinary tract infection. Based on these results, we conclude that patients older than 65 years, with metastases at multiple sites, intestinal obstruction, preoperative carcinoembryonic antigen level 2:500 ng/ml, lactate dehydrogenase >35O units/liter, hemoglobin <10 mg/dl, or hepatic parenchymal replacement by tumor >25 percent have poor prognosis for surgical intervention. CONCLUSION: Whether to perform primary tumor resection in patients with asymptomatic Stage IV colorectal cancer remains controversial; however, the more aggressively we perform radical resection and metastasectomy to selected patients, the more survival benefits the patients obtain.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23–47.
Department of Health, Executive Yuan, Republic of China: Cancer Registry Annual Report, Republic of China, 1998. Taipei: Department of Health, Executive Yuan, 2001.
Steinberg SM, Barkin JS, Kaplan RS, Stablein DM. Prognostic indicators of colon tumor: the gastrointestinal tumor study group experience. Cancer 1986;57:1866–70.
Jessup JM, Stewart AK, Menck HR. The National Cancer Database report on patterns of care for adenocarcinoma of the rectum, 1985-1995. Cancer 1998;83:2408–18.
Joffe J, Gordon PH. Palliative resection for colorectal carcinoma. Dis Colon Rectum 1981;24:355–60.
Makela J, Haukipuro K, Laitinen S, Kairaluoma MI. Palliative operations for colorectal cancer. Dis Colon Rectum 1990;33:846–50.
Rosen SA, Buell JF, Yoshida A,et al. Initial presentation with Stage IV colorectal cancer: how aggressive should we be? Arch Surg 2000;135:53O-5.
Sarela AI, Guthrie JA, Seymour MT, Ride E, Guillou PJ, O’Riordain DS. Non-operative management of the primary tumor in patients with incurable Stage IV colorectal cancer. Br J Surg 2001;88:1352–6.
Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with Stage IV disease. Ann Surg Oncol 1999;6:651–7.
Buechter KJ, Boustany C, Caillouette R, Cohn IJ. Surgical management of the acutely obstructed colon. A review of 127 cases. Am J Surg 1988;156:l63–8.
Mclntyre R, Reinbach D, Cushieri A. Emergency abdominal surgery in the elderly. J R Coll Surg Edin 1997;42:173–8.
Liu SK, Church JM, Lavery IC, Fazio VW. Operation in patients with incurable colon cancer: is it worthwhile? Dis Colon Rectum 1997;40:11–4.
Sarela A, O’Riordain DS. Rectal adenocarcinoma -with liver metastases: management of the primary tumour. Br J Surg 2001;88:l63–4.
Camunez F, Echenagusia A, Simo G, Turegano F, Vazquez J, Barreiro-Meiro I. Malignant colorectal obstruction treated by means of self-expanding metallic stents: effectiveness before surgery and in palliation. Radiology 2000;2l6:492–7.
Cole SJ, Boorman P, Osman H, Sathananthan N, Parker MC. Endoluminal stenting for relief of colonie obstruction is safe and effective. Colorectal Dis 2000;2:282–7.
Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000;321:531–5.
Wilke H, Stahl M. Colorectal cancer and metastasectomy: treatment of advanced disease. Ann Oncol 2000; 11(Suppl3):45–9.
Shimada Y, Yoshino M, Wakui A,et al. Phase II study of CPT-11, a new camptothecin derivation, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993;ll:909–13.
Rougier P, Bugat R, Douillard JY,et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251–60.
Cunningham D, Pyrhonen S, James RD,et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413–8.
Vamvakas L, Kakolyris S, Kouroussis C,et al. Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. Am J Clin Oncol 2002;25:65–70.
Machover D, Diaz-Rubio E, de Gramont A,et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95–8.
Diaz-Rubio E, Sastre J, Zaniboni A,et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998;9:105–8.
Becouarn Y, Gamelin E, Coudert B,et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patient. J Clin Oncol 2001;19:4l95–201.
Goslin R, Steele G, Zamcheck N, Mayer R, Maclntyre J. Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum.Dis Colon Rectum 1982;25;749–53.
Adam R. The importance of visceral metastasectomy in colorectal cancer. Ann Oncol 2000;11(Suppl3):29–36.
Choti MA, Sitzmann JV, Tiburi MF,et al. Trends in long-term following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759–66.
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg 1999;230:309–21.
Santibanes ED, Lassalle FB, McCormack L,et al. Simultaneous colorectal and hepatic resection for colorectal cancer: postoperative and long-term outcomes. J Am Coll Surgeons 2002;195:196–202.
Toshiniko S, Noriaki T, Koichiro I, Tsuyoshi Y, Hidehito M, Masahiro Y. Pulmonary resection for metastases from colorectal cancer. Chest 2001;119:1069–72.
Rizk NP, Downey RJ. Resection of pulmonary metastases from colorectal cancer. Semin Thorac Cardiovasc Surg 2002;l4:29–34.
Headrick JR, Miller DL, Nagorney DM,et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001;71:975–9.
Author information
Authors and Affiliations
About this article
Cite this article
Kuo, LJ., Leu, SY., Liu, MC. et al. How aggressive should we be in patients with stage iv colorectal cancer?. Dis Colon Rectum 46, 1646–1652 (2003). https://doi.org/10.1007/BF02660770
Issue Date:
DOI: https://doi.org/10.1007/BF02660770